Mumbai, July 14, 2017: Pahrma Major, Jubilant Life Sciences today said its subsidiary has received an abbreviated new drug application (ANDA) final approval for Bupropion Hydro chloride extended-release tablets USP (XL), 150 mg and 300 mg. Bupropion Hydro chloride extended-release tablets, used for the treatment of major depressive disorder and prevention of seasonal effective disorder,company said in a filing with BSE. The approved product is the generic version of Well but rin XL of Valeant, which is used for the treatment of major depressive disorder and prevention of seasonal effective disorder. This is the fourth approval received by the company from the USFDA during the current financial year. As on March 31, 2017, Jubilant Life Sciences had 81 ANDAs for oral solids filed in the US, of which 51 have been approved, the filing added.
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as…
Previously, the patient underwent an above-knee amputation in the USA due to similar complications in the…
New Delhi, December 27, 2024: A team of expert obstetricians & neonatologists at Motherhood Hospitals,…
By Dr. Khushali Lalcheta, Consultant Physician, HCG Hospitals, Rajkot Diabetes is often a misunderstood condition that…
By Dr. Balaji B S, Consultant - Neurology & Epileptology, Aster Whitefield Hospital, Bengaluru Foreign…
New Delhi, December 27, 2024: Aakash Healthcare Super Specialty Hospital, New Delhi, has taken a…